2023-08-03 22:59:24
Review and Assessment Service, Disclosure of review results of the Drug Evaluation Committee in August
Coselugo Re-discussion-Reblol Non-salary
GlaxoSmithKline’s endometrial cancer treatment Gemperi Inj (dostalimab), Ono Pharmaceutical Korea’s direct-crystal cancer treatment Viratovicapsule (Encorafenib), Korea Roche’s optica neuromyelitis category disease treatment Enspring Prefilled Syringe Inj (Satralizumab) ) crossed the first barrier of salary.
BMS Korea’s ulcerative colitis treatment Zeposia Capsule (ozanimod hydrochloride) passed conditionally and virtually completed the evaluation of the adequacy of reimbursement.
On the other hand, the same company’s myelodysplastic syndrome treatment Reblozil Injection (Ruspartercept) was decided not to be covered. AstraZeneca Korea decided to re-discuss Coselugo Capsule (Selumetinib Sulfate), a neurofibroma treatment.
The Health Insurance Review and Assessment Service held a Pharmaceutical Reimbursement Evaluation Committee on the 3rd and disclosed the results of the review.
On this day, a total of six new drugs to be registered were raised as an agenda for reviewing the adequacy of medical care benefits. Among them, three of them, including Zempery, Viratovi Capsule, and Nspiring, completed the deliberation with ‘salary suitability’. it has passed
Zempery is ‘recurrent or progressive mismatch repair defect (dMMR)/high frequency microsatellite instability (MSI-H) endometrial cancer’, Viratobi is ‘BRAF V600E mutation confirmed metastatic colorectal cancer’, Nspiring is ‘ Anti-aquaporin-4 (AQP4) antibody-positive adult neuromyelitis optica is used for the treatment of ‘categorical disease’.
Zeposia, which is used for moderate to severe active ulcerative colitis, was evaluated as having appropriateness of benefit when accepted below the assessed amount. It was passed conditionally, but in fact, it can be said that it has crossed the first barrier. Zeposia was reviewed together with 0.92mg capsules and 0.23/0.46mg capsule starter packs.
On the other hand, levolozil is the only drug administered to patients with myelodysplastic syndrome (NDS-RS) or myelodysplasia/myeloproliferative tumor (MDS/MPN-RS-T) or adult beta thalassemia requiring red blood cell transfusion. The review was completed without pay.
Cocelluco, a treatment for neurofibromatosis type 1 with gunshot neurofibroma, was pending with the Pharmaceutical Review Committee due to re-discussion.
The HIRA said, “The final evaluation result may be changed in the event of changes in the detailed reimbursement scope and standard items of the drug, changes in approval details or withdrawal (cancellation) of the item for which a decision has been applied.”
© News The Voice Healthcare Unauthorized reproduction and redistribution prohibited
1691104284
#Jempery #Viratovi #Nspring #passed #salary #gate.. #Zeposia #conditional
